Barclays Downgrades Charles River Labs (CRL) to Equal Weight
More News related to CRL
- Barclays Downgrades Charles River Labs (CRL) to Equal Weight
- Morning Movers 11/04: MPAC, ABK, GNVC, RHB, IRE, PACR Higher; STEC, CLRT, VG, TRLG, ANSW Lower
- After-Hours Movers 11/03: QLTY, PACR, BGCP, TESO Higher; STEC, TRLG, CLRT, CRL, MYGN Lower
- Charles River (CRL) Beats Q3 Views by 5c; Lowers FY09 EPS Guidance
- Charles River Announces Third-Quarter 2009 Results
More News related to Downgrades
- After-Hours Movers 11/23: CNO, RMBS, NUAN, ADI Higher; HAYN, DY, DBLE, CISG, IPAR, KWR Lower
- Trading Radar for 11/24: Heinz (HNZ), Dollar Tree (DLTR), Eaton Vance (EV), Hormel Foods (HRL), J. Crew (JCG) Report
- Afternoon ETF Check: GDX, KBE Higher; UUP Lower
- Unusual 11 Mid-Day Movers 11/23: ABIO, SEED, FNET, CDTI Higher; NYNY, GGR, TTIL, PEET Lower
- Best of the Web 11/23: Suicides On the Rise, U.S. Debt Service Could Top $700B, Really? An Insider Trading Beauty Queen
Barclays downgrades Charles River Labs (NYSE: CRL) from Overweight to Equal Weight, while maintaining their $36 price target.
Charles River Laboratories International, Inc. (Charles River) is a global provider of solutions that advance the drug discovery and development process, including research models and associated services, and outsourced preclinical services.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
